ライフサイエンスコーパス: University of California

1 National Institutes of Health, University of California, Abbott Laboratories, and the C

2 University of California and the Safeway Foundation.

3 ectal cancer patients from registries at the University of California and Veterans Administration hos

4 e example of collaboration between academia (University of California) and industry (Sangamo), Hoban

5 d up receiving an excellent education at the University of California at Berkeley and postdoctoral tr

6 en sera accrued between 1959 and 1966 by the University of California at Berkeley Child Health and De

7 The Department of Plant Pathology at the University of California at Berkeley was destroyed as a

8 as a graduate student with Matt Welch at the University of California at Berkeley, my interest was pi

9 se tolerance and diabetes onset in UCD-T2DM (University of California at Davis type 2 diabetes mellit

10 e University of Hawaii and my Ph.D. from the University of California at Davis.

11 erface called Cyber-T that is located on the University of California at Irvine genomics web site.

12 Using a modification of the RAND/University of California at Los Angeles appropriateness

13 parallel, three-way replication of the RAND-University of California at Los Angeles appropriateness

14 ton second chromosome deficiency kit and the University of California at Los Angeles Bruinfly FRT40A-

15 nsecutive liver transplants performed at the University of California at Los Angeles during a 6-year

16 sity of Pennsylvania School of Medicine, the University of California at Los Angeles School of Medici

17 of the Department of Plant Pathology at the University of California at Riverside the same year and

18 in the Rancho Bernardo Study (n=196) and the University of California at San Diego's Filipino Women's

19 ced, malignant, incurable solid tumours from University of California at San Diego, CA, USA, and Sara

20 l developed by the Palsson Laboratory at the University of California at San Diego.

21 University of California at San Francisco criteria, alph

22 atory bowel disease from 1990 to 2015 at the University of California at San Francisco Medical Center

23 of 417 primary cutaneous melanomas from the University of California at San Francisco Melanoma Cente

24 ornia at Los Angeles School of Medicine, the University of California at San Francisco School of Medi

25 e past 20 years in the Tetrad program at the University of California at San Francisco to identify un

26 el- strain (mel2), obtained from J.C. Edman (University of California at San Francisco, CA), produced

27 lege of Wisconsin, University of Cincinnati, University of California at San Francisco, University of

28 a 5-year longitudinal MS cohort study at the University of California at San Francisco.

29 ment of a tiered museum-based program at the University of California, Berkeley as a model for engagi

30 ods, developed by linguists Johanna Nichols (University of California, Berkeley), Donald Ringe and An

31 rly studies of bees, (c) student work at the University of California, Berkeley, (d) work at the Amer

32 merases continued throughout my years at the University of California, Berkeley, and Harvard.

33 biosynthesis of plant polysaccharides at the University of California, Berkeley, led me, rather impro

34 VIZARD is a Java program created at the University of California, Berkeley, to facilitate analys

35 d by his family, and then transferred to the University of California, Berkeley, to major in entomolo

36 George Oster is Professor of Biophysics, University of California, Berkeley.

37 ons under the guidance of H.A. Barker at the University of California, Berkeley.

38 s, and coenzymes with Professor Snell at the University of California-Berkeley, it was rational to be

39 weeks (July-Oct 1998) of observations at the University of California, Blodgett Forest field station

40 ly approach, while Christopher Polage of the University of California Davis and Mark Wilcox of Leeds

41 t accrual into cancer clinical trials at the University of California Davis Cancer Center.

42 s published in this issue resulting from the University of California Davis Cardiovascular Symposium

43 group of scientists convened as part of the University of California Davis Cardiovascular Symposium

44 s published in this issue resulting from the University of California Davis Cardiovascular Symposium

45 Prospective observational study at the University of California Davis Medical Center (Sacrament

46 peration within 60 minutes of arrival at the University of California Davis Medical Center.

47 esolution imaging systems constructed at the University of California Davis were used to acquire reti

48 years treated for blunt torso trauma at the University of California, Davis Medical Center, a level

49 ducted at the Imaging Research Center of the University of California, Davis, from November 2004 thro

50 31, 2013, at the Vascular Laboratory of the University of California, Davis, Medical Center were inc

51 , through May 31, 2004, was conducted at the University of California, Davis, Medical Center.

52 derwent cutaneous surgical procedures at the University of California, Davis, outpatient dermatology

53 simulation experiments were conducted at the University of California, Davis, research CAFO.

54 ated the effects of leptin administration in University of California, Davis, type 2 diabetes mellitu

55 iversity in Uganda, a sabbatical year in the University of California, Davis, where I became aware of

56 Center for Healthcare Policy and Research, University of California, Davis.

57 ll vial culture currently implemented at the University of California-Davis Medical Center hospital.

58 is a report of a series of 2 patients at the University of California-Davis Medical Center treated be

59 being trained as a plant pathologist at the University of California-Davis, an institution that prid

60 The University of California-Davis_Primary (UCD_P) chemical

61 The University of California-Davis_Primary (UCD_P) model was

62 pecimens were evaluated; 1,806 were from the University of California Irvine Medical Center Medical M

63 December 2, 2010, and June 11, 2012, at the University of California Irvine Medical Center.

64 The 3-dimensional University of California Irvine-California Institute of

65 DOSI instruments were constructed at the University of California, Irvine (Irvine, CA), and deliv

66 ifier outputs, biomedical data sets from the University of California, Irvine (UCI) Machine Learning

67 Testing with datasets from the UCI (University of California, Irvine) Machine Learning Repos

68 In 1984, I moved to the University of California, Irvine, and initiated research

69 National Cancer Institute compounds and the University of California, Irvine, ChemDB database result

70 study of aging and dementia performed at the University of California, Irvine, from January 1, 2003,

71 ng in patients with BCC was performed at the University of California-Irvine Health Beckman Laser Ins

72 Between August 2012 and May 2013, the University of California Los Angeles (UCLA) preschool vi

73 e recommendations using the RAND Corporation-University of California Los Angeles Appropriateness Met

74 nts out of 661 undergoing nephrectomy at the University of California Los Angeles between 1989 and 19

75 ds of 661 patients undergoing nephrectomy at University of California Los Angeles between 1989 and 19

76 trisegment graft that were performed at the University of California Los Angeles between 9/91 and 02

77 aparoscopic donor nephrectomies performed at University of California Los Angeles between August 1999

78 nts were identified from the database of the University of California Los Angeles Kidney Cancer Progr

79 the Fontan registries of the Mayo Clinic and University of California Los Angeles Medical Center resp

80 lth Survey and a validated short form of the University of California Los Angeles Prostate Cancer Ind

81 ersity of Southern California and the Harbor University of California Los Angeles Research and Educat

82 usetts General Hospital, Boston, MA, and the University of California Los Angeles, Ronald Reagan Medi

83 Research AND Development Corporation (RAND)/University of California, Los Angeles (UCLA) Appropriate

84 luded studies performed after I moved to the University of California, Los Angeles (UCLA), including

85 uate students in an organized program at the University of California, Los Angeles (UCLA), we have un

86 The data coordinating centre at the University of California, Los Angeles (UCLA, CA, USA), r

87 Patients with advanced HF referred to University of California, Los Angeles (UCLA; n=2255), we

88 Center for Advancing Translational Science (University of California, Los Angeles [CA, USA] Clinical

89 asures for validity on the basis of the RAND/University of California, Los Angeles Appropriateness Me

90 We used the RAND Corporation/University of California, Los Angeles Appropriateness Me

91 Jonsson Comprehensive Cancer Center and the University of California, Los Angeles Department of Urol

92 obtained from all patients undergoing ITx at University of California, Los Angeles from July 2008 to

93 merica at the Jules Stein Eye Institute, the University of California, Los Angeles in 2004.

94 oduce integrated staging systems such as the University of California, Los Angeles Integrated Staging

95 blation procedures (n=24; 50% paroxysmal) at University of California, Los Angeles Medical Center wer

96 ective/Management (LENT/SOM) scales, and the University of California, Los Angeles Prostate Cancer In

97 d, leaving a 34-item revised instrument (the University of California, Los Angeles Scleroderma Clinic

98 ed Glaucoma Intervention Study and the UCLA (University of California, Los Angeles) Jules Stein Eye I

99 was designed by Wu Lab (School of Dentistry, University of California, Los Angeles) to measure the di

100 0, 2017, at the Stein Eye Institute at UCLA (University of California, Los Angeles).

101 the Department of Pathology Registry at the University of California, Los Angeles, and analyzed for

102 founded the Jules Stein Eye Institute at the University of California, Los Angeles, and led a multiye

103 1 KEYNOTE-001 trial at a single institution (University of California, Los Angeles, CA, USA).

104 agnosed, suspected genetic conditions at the University of California, Los Angeles, Clinical Genomics

105 ile they were undergoing hemodialysis at the University of California, Los Angeles, dialysis center.

106 microPET, was designed and developed at the University of California, Los Angeles, for imaging small

107 ollected at the Department of Ophthalmology, University of California, Los Angeles, from May 1 to Jul

108 rked on diseases of ornamental plants at the University of California, Los Angeles, starting in 1939,

109 ruary 1, 1990, and November 30, 2010, at the University of California, Los Angeles, were matched in a

110 doe-mbi.ucla.edu/people/parag/P A_HOME/, the University of California, Los Angeles-Department of Ener

111 the Ahmanson-Lovelace Brain Mapping Center, University of California, Los Angeles.

112 control individuals from 2015 to 2016 at the University of California, Los Angeles.

113 99 to April 2012 at the Stein Eye Institute, University of California, Los Angeles.

114 A University of California, Los Angeles/Kaiser Permanente

115 vely, compared to 21.1 and 7.6 months in the University of California, Los Angeles/KPLA control cohor

116 oved PFS without improved OS compared to the University of California, Los Angeles/KPLA control group

117 2 rounds on a scale of 1 to 9 using the RAND/University of California-Los Angeles modified-Delphi met

118 Data were derived from the University of California Lupus Outcomes Study, a longitu

119 CT examinations in 2609 children at the five University of California medical centers during 2013.

120 A key secondary measure was the University of California Performance-based Assessment-Ex

121 composition are revisited using 15 years of University of California, Riverside/CE-CERT environmenta

122 SETTING: Hamilton Glaucoma Center, University of California San Diego.

123 horts: mainly non-severe asthmatics from the University of California San Francisco (UCSF) and mainly

124 Using a combination of FDG-PET and University of California San Francisco (UCSF) criteria,

125 n Criteria and an additional 26 (10%) within University of California San Francisco (UCSF) criteria.

126 from June 3, 2012, to April 26, 2014, at the University of California San Francisco (UCSF) Medical Ce

127 The third cohort of 120 patients from the University of California San Francisco (UCSF) was includ

128 h advanced fibrosis in the discovery cohort (University of California San Francisco [UCSF], N = 433),

129 The Committee of Human Research of the University of California San Francisco approved this stu

130 includes 243 listed (105 M+ group, 76 beyond University of California San Francisco criteria; 210 tra

131 iverse ambulatory nephrology practice at the University of California San Francisco during calendar y

132 In 1996, the University of California San Francisco Gynecologic Oncol

133 isk of death in four intensive care units at University of California San Francisco Medical Center fr

134 ted at San Francisco General Hospital or the University of California San Francisco Medical Center.

135 A data set of 526 patients from the University of California San Francisco Melanoma Center w

136 We screened the University of California San Francisco Memory and Aging

137 isease AAO in an independent cohort from the University of California San Francisco Memory and Aging

138 e (SICCA) who presented for follow-up at the University of California San Francisco, Aravind Eye Hosp

139 c hypersensitivity pneumonitis, one from the University of California San Francisco, CA, USA (UCSF),

140 ter, Dallas, TX; Dr. Elizabeth H. Blackburn, University of California San Francisco, CA; and Dr. Mari

141 007 in the neuro-ophthalmology clinic at the University of California San Francisco.

142 , 308 LRT and 120 LURT were performed at the University of California San Francisco.

143 due to IgA nephropathy were performed at the University of California San Francisco.

144 nalysis, [GPA]) and 21 healthy eyes from the University of California, San Diego (UCSD) Diagnostic In

145 ts from June 2003 until December 2009 at the University of California, San Diego (UCSD), Medical Cent

146 uenza A virus within the student body of the University of California, San Diego (UCSD), sampling for

147 ment to assess decision-making capacity: the University of California, San Diego Brief Assessment of

148 r =4 retinal tomographic examinations in the University of California, San Diego Diagnostic Innovatio

149 Dyspnea Index total score or 5 units in the University of California, San Diego Shortness of Breath

150 efined by 48-week worsening of FVC, dyspnea (University of California, San Diego Shortness of Breath

151 wed up at the Visual Performance Laboratory, University of California, San Diego, at 6-month interval

152 ial conducted at an academic medical center, University of California, San Diego, between July 2011 a

153 Flossie Wong-Staal (University of California, San Diego, CA).

154 controls were taken on a 25-min walk on the University of California, San Diego, campus during which

155 d for up to 6 years in cohort studies at the University of California, San Diego, HIV Neurobehavioral

156 arold Varmus and Roel Nusse, was held at the University of California, San Diego, in June 2007.

157 rials from March 2001 to October 2012 at the University of California, San Diego, Medical Center in L

158 1,645 HIV-infected patients followed at the University of California, San Diego, Medical Center in S

159 At the University of California, San Diego, Medical Center, our

160 ic and Mohs Micrographic Surgery Unit of the University of California, San Diego, Medical Center.

161 and functional capacity, as measured by the University of California, San Diego, Performance-Based S

162 Total scores on the University of California, San Diego, Performance-Based S

163 vities of daily living, as measured with the University of California, San Diego, Performance-Based S

164 A symposium was held at the University of California, San Diego, to honor the contri

165 University, The Netherlands) and Yunde Zhao (University of California, San Diego, USA).

166 rs at the Alzheimer Disease Research Center, University of California, San Diego.

167 ildren at San Diego State University and the University of California, San Diego.

168 ed or suspect glaucoma were recruited at the University of California, San Diego.

169 University of California, San Diego.

170 from a longitudinal prospective study at the University of California, San Diego.

171 ducted at the Visual Performance Laboratory, University of California, San Diego.

172 ase-control studies in the United States and University of California, San Francisco (1991-2004)) and

173 =5 cm or </=3 nodules measuring </=3 cm) and University of California, San Francisco (single tumor me

174 maximum of 3 total tumors with none >3 cm), University of California, San Francisco (UCSF) criteria

175 likely to have 1 lesion, tumors within Milan/University of California, San Francisco (UCSF) criteria,

176 [CN] controls) from the San Francisco-based University of California, San Francisco (UCSF) Memory an

177 les from 51 patients with RA enrolled in the University of California, San Francisco (UCSF) RA Cohort

178 ing these financial threats, research at the University of California, San Francisco (UCSF), has unde

179 ata from 338 BAVM cases participating in the University of California, San Francisco (UCSF)-Kaiser Br

180 ans of NBS for SCID who received care at the University of California, San Francisco (UCSF).

181 y Prostate Active Surveillance Study (PASS); University of California, San Francisco (UCSF); and Univ

182 recruited patients scheduled for DBS at the University of California, San Francisco and the San Fran

183 uited consecutively from 2001 to 2013 at the University of California, San Francisco and the Universi

184 VGKCc/LGI1-Ab encephalitis evaluated in the University of California, San Francisco Autoimmune Encep

185 valuated at the Multiple Sclerosis Center at University of California, San Francisco between July 200

186 of Biostatistics He is also a member of the University of California, San Francisco Cardiovascular R

187 r Health Policy Studies and Co-leader of the University of California, San Francisco Comprehensive Ca

188 Providers at University of California, San Francisco have been at the

189 sly secret tobacco industry documents in the University of California, San Francisco Legacy Tobacco D

190 pus erythematosus (SLE) participating in the University of California, San Francisco Lupus Outcomes S

191 Data were derived from the University of California, San Francisco Lupus Outcomes S

192 Chapel Hill), and cardiology training at the University of California, San Francisco Medical Center.

193 t the pediatric multiple sclerosis center of University of California, San Francisco or State Univers

194 The present study uses data from the University of California, San Francisco RA Panel Study i

195 The present study uses data from the University of California, San Francisco RA Panel Study,

196 sed 231 women with RA who are members of the University of California, San Francisco RA Panel Study.

197 obacco Control Research and Education at the University of California, San Francisco School of Medici

198 ., Indiana University, Indianapolis, and the University of California, San Francisco) compared CHL wi

199 10 and who radiologically met Milan or UCSF (University of California, San Francisco) criteria, 1-yea

200 sed molecular graphics package UCSF CHIMERA (University of California, San Francisco).

201 radiographic images from 179 aneurysm cases (University of California, San Francisco, 1990--1997) to

202 ed at teaching hospitals affiliated with the University of California, San Francisco, and a required

203 at the Hunters Point Animal Facility at the University of California, San Francisco, and all experim

204 Mexico's Ministry of Health, University of California, San Francisco, and Bill & Meli

205 at Aravind Eye Hospital, Proctor Foundation, University of California, San Francisco, and Dartmouth-H

206 s of a study of postdoctoral outcomes at the University of California, San Francisco, and suggest tha

207 University of California, San Francisco, and the U.S. De

208 itial conformations generated by CombiBuild (University of California, San Francisco, CA, 1995), we h

209 were enrolled in the intensive care units at University of California, San Francisco, CA, USA, Stanfo

210 ostexposure prophylaxis protocol used at the University of California, San Francisco, can be reviewed

211 with HCC larger than the proposed Milan and University of California, San Francisco, criteria experi

212 children with HCC larger than the Milan and University of California, San Francisco, criteria.

213 Mobile Mammography Screening Program of the University of California, San Francisco, from April 1985

214 ively recruited from glaucoma clinics at the University of California, San Francisco, from January 20

215 3 University of California, San Francisco, hospitals.

216 stematic application of fetal surgery at the University of California, San Francisco, in the early 19

217 approved by and executed in accordance with University of California, San Francisco, institutional a

218 This retrospective case series at the University of California, San Francisco, Medical Center,

219 d patients with progranulin mutations at the University of California, San Francisco, Memory and Agin

220 review of 2397 patients who were seen at the University of California, San Francisco, Memory and Agin

221 ted from electronic medical records from the University of California, San Francisco, Multiple Sclero

222 ed in the Cardiovascular Research Institute, University of California, San Francisco, on blood sample

223 diverse referred sample of women seen at the University of California, San Francisco, Polycystic Ovar

224 The present study uses data from the University of California, San Francisco, RA Panel Study

225 (1997 and 1998) through interviews with the University of California, San Francisco, RA panel.

226 The study was conducted in the University of California, San Francisco, Retina Clinic b

227 ted over 3 years through interviews with the University of California, San Francisco, Rheumatoid Arth

228 academic tertiary referral medical centers: University of California, San Francisco, University of P

229 east GFP fusion localization database by the University of California, San Francisco, USA (UCSF).

230 Men managed with AS at University of California, San Francisco, were classified

231 and Bharatpur Eye Hospital in Nepal, and the University of California, San Francisco, who had culture

232 o were receiving maintenance hemodialysis at University of California, San Francisco-affiliated dialy

233 to radiation and were treated surgically at University of California, San Francisco-affiliated hospi

234 SETTING Memory and Aging Center, University of California, San Francisco.

235 ents with non-squamous NSCLC resected at the University of California, San Francisco.

236 between September 1996 and December 2003 at University of California, San Francisco.

237 stitutes of Health ARDS Network trial at the University of California, San Francisco.

238 the Adult Echocardiography Laboratory at the University of California, San Francisco.

239 dministration Medical Center, San Francisco, University of California, San Francisco.

240 Canadian Institutes of Health Research; and University of California, San Francisco.

241 ing Center of the Department of Neurology at University of California, San Francisco.

242 orenstein Endowed Chair in Cardiology at the University of California, San Francisco.

243 er Center and the Mt Zion Health Fund of the University of California, San Francisco.

244 recruited from ophthalmology clinics at the University of California, San Francisco.

245 e performed at the Mission Bay Campus of the University of California, San Francisco.

246 ce of pathologic HCC findings outside of the University of California-San Francisco criteria (P=0.001

247 ed from the Multiple Sclerosis Center at the University of California-San Francisco.

248 2 and 2012 at 3 academic transplant centers (University of California-San Francisco; Mayo Clinic, Roc

249 bstantial false positives in the widely used University of California Santa Cruz (UCSC) annotations,

250 The University of California Santa Cruz (UCSC) Gene Sorter h

251 The University of California Santa Cruz (UCSC) Genome Bioinf

252 ed, configured and fully integrated into the University of California Santa Cruz (UCSC) Genome Browse

253 The University of California Santa Cruz (UCSC) Genome Browse

254 The University of California Santa Cruz (UCSC) Genome Browse

255 The University of California Santa Cruz (UCSC) Genome Browse

256 small virtual machine version of the popular University of California Santa Cruz (UCSC) Genome Browse

257 The University of California Santa Cruz (UCSC) Known Genes d

258 The University of California Santa Cruz (UCSC) Proteome Brow

259 The University of California Santa Cruz (UCSC) Table Browser

260 echnology Information, Genome Browser at the University of California Santa Cruz and the disease port

261 The University of California Santa Cruz Genome Browser Datab

262 The variation resources within the University of California Santa Cruz Genome Browser inclu

263 The University of California Santa Cruz Genome Browser offer

264 use publicly available data tracks from the University of California Santa Cruz Genome Browser to in

265 results can be visualized locally or in the University of California Santa Cruz Genome Browser.

266 promoter retrieval and visualization in the University of California Santa Cruz Genome Browser.

267 the Wellcome Trust Sanger Institute and the University of California Santa Cruz, provide coordinated

268 and intuitive programmatic interface to the University of California, Santa Cruz (UCSC) genome brows

269 The University of California, Santa Cruz (UCSC) Genome Brows

270 Since its 2001 debut, the University of California, Santa Cruz (UCSC) Genome Brows

271 The University of California, Santa Cruz (UCSC) Interaction

272 The ENCODE Data Coordination Center at The University of California, Santa Cruz (UCSC) is the prima

273 3), two consecutive releases by the IHGSC at University of California, Santa Cruz (UCSC), two consecu

274 of the annotation tracks are computed at the University of California, Santa Cruz from publicly avail

275 The University of California, Santa Cruz Genome Browser Data

276 The University of California, Santa Cruz Genome Browser offe

277 ENCODE Data Coordination Center (DCC) at the University of California, Santa Cruz serves as the centr

278 The University of California, Santa Cruz, Genome Browser Dat

279 The University of California, Santa Cruz, makes this data av

280 A microfluidic device is being developed by University of California-Santa Barbara as part of a join

281 l, a decision by Stanford University and the University of California to seek patents on the technolo

282 scribe the impact my graduate studies at the University of California (UC)-Davis had on my career.

283 The analysts from the University of California who conducted the medical effec